Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Ragothaman Srinivasan

Recap Of Friday's Biotech Catalysts - End Of the Day Summary

  • Pfizer (NYSE:PFE) announced positive top-line results from its pivotal U.S. Phase 3 study in infants evaluating its 20-valent pneumococcal conjugate vaccine candidate (20vPnC) for the prevention of invasive pneumococcal disease (IPD). The study met two co-primary objectives, associated with immunogenicity responses. Pfizer shares traded in a range of $48.55 to $50.39 on a day volume of 24.91 million shares, closed regular trading session at $50.11.
  • The European Commission has granted orphan medicinal product designation in the EU to Relief Therapeutics and Acer Therapeutics’  (NASDAQ:ACER) lead asset ACER-001 (sodium phenylbutyrate) for the potential treatment of patients with Maple Syrup Urine Disease (MSUD). Acer shares traded in a range of $1.45 to $1.56 on a day volume of 319.36 thousand shares, closed regular trading session at $1.47.
Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.